Technical Analysis for SNY - Sanofi

Grade Last Price % Change Price Change
grade B 44.26 -2.58% -1.17
SNY closed down 2.58 percent on Friday, March 22, 2019, on 2.7 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical SNY trend table...

Date Alert Name Type % Chg
Mar 22 Cup with Handle Other 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 22 Gapped Down Weakness 0.00%
Mar 21 Cup with Handle Other -2.58%
Mar 21 Inside Day Range Contraction -2.58%
Mar 21 Overbought Stochastic Strength -2.58%
Mar 21 Up 3 Days in a Row Strength -2.58%
Mar 20 New Uptrend Bullish -2.53%
Mar 20 Overbought Stochastic Strength -2.53%
Mar 19 Cup with Handle Other -1.95%

Older signals for SNY ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Its principal products include Lantus and Apidra analogs of human insulin; Insuman, a range of human insulin solutions and suspensions; Amaryl, an oral once-daily sulfonylurea; BGStar and iBGStar blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aubagio, an oral immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for various cancer types; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company's products also consist of thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines include Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela oral phosphate binders used in patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis of certain joints; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products to treat fever, pain, and digestive health areas; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has alliance arrangements with Bristol-Myers Squibb, Regeneron, and Warner Chilcott. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.
Cancer Healthcare Life Sciences Pharmaceutical Industry Pain Pharmaceuticals Prostate Cancer Health Sciences Dialysis Influenza Multiple Sclerosis Chronic Kidney Disease Osteoarthritis Colorectal Cancer Hypertension Healthcare Products Insulin Cac 40 Hepatotoxins Bristol Myers Squibb Sanofi Fever Gaucher Disease Pneumonia Pompe Disease Thrombosis Consumer Health Care Products Deep Vein Thrombosis Enzyme Replacement Therapies Regeneron
Is SNY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 45.62
52 Week Low 37.43
Average Volume 1,018,243
200-Day Moving Average 42.817
50-Day Moving Average 42.7346
20-Day Moving Average 43.388
10-Day Moving Average 44.569
Average True Range 0.5988
ADX 26.31
+DI 34.1195
-DI 22.93
Chandelier Exit (Long, 3 ATRs ) 43.7636
Chandelier Exit (Short, 3 ATRs ) 42.4464
Upper Bollinger Band 46.2029
Lower Bollinger Band 40.5731
Percent B (%b) 0.65
BandWidth 12.975477
MACD Line 0.7273
MACD Signal Line 0.5571
MACD Histogram 0.1702
Fundamentals Value
Market Cap 111.16 Billion
Num Shares 2.51 Billion
EPS 4.31
Price-to-Earnings (P/E) Ratio 10.27
Price-to-Sales 2.74
Price-to-Book 1.72
PEG Ratio 1.86
Dividend 1.64
Dividend Yield 3.71%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.09
Resistance 3 (R3) 45.13 44.90 44.95
Resistance 2 (R2) 44.90 44.69 44.88 44.90
Resistance 1 (R1) 44.58 44.56 44.47 44.54 44.86
Pivot Point 44.35 44.35 44.29 44.33 44.35
Support 1 (S1) 44.03 44.14 43.92 43.99 43.66
Support 2 (S2) 43.80 44.01 43.78 43.62
Support 3 (S3) 43.48 43.80 43.57
Support 4 (S4) 43.44